S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
NASDAQ:BIIB

Biogen (BIIB) Stock Forecast, Price & News

$199.65
+6.56 (+3.40%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$194.50
$199.78
50-Day Range
$187.54
$223.02
52-Week Range
$187.16
$468.55
Volume
972,301 shs
Average Volume
1.29 million shs
Market Capitalization
$29.24 billion
P/E Ratio
20.44
Dividend Yield
N/A
Beta
0.42
30 days | 90 days | 365 days | Advanced Chart
Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

Biogen logo

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Headlines

Biogen (NASDAQ:BIIB) PT Lowered to $210.00
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
9,610
Year Founded
1978

Sales & Book Value

Annual Sales
$10.98 billion
Cash Flow
$27.73 per share
Book Value
$76.62 per share

Profitability

Net Income
$1.56 billion
Pretax Margin
15.02%

Debt

Price-To-Earnings

Miscellaneous

Free Float
145,661,000
Market Cap
$29.24 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/03/2022
Today
5/20/2022
Next Earnings (Estimated)
7/28/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.29 out of 5 stars

Medical Sector

276th out of 1,420 stocks

Biological Products, Except Diagnostic Industry

45th out of 209 stocks

Analyst Opinion: 4.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Biogen (NASDAQ:BIIB) Frequently Asked Questions

Is Biogen a buy right now?

32 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 16 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Biogen stock.
View analyst ratings for Biogen
or view top-rated stocks.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Thursday, July 28th 2022.
View our earnings forecast for Biogen
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings results on Tuesday, May, 3rd. The biotechnology company reported $3.62 earnings per share for the quarter, missing the consensus estimate of $4.41 by $0.79. The biotechnology company earned $2.53 billion during the quarter, compared to analyst estimates of $2.50 billion. Biogen had a net margin of 13.40% and a trailing twelve-month return on equity of 23.46%. Biogen's quarterly revenue was down 6.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.34 earnings per share.
View Biogen's earnings history
.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of $14.25-$16.00 for the period, compared to the consensus estimate of $15.44. The company issued revenue guidance of $9.70 billion-$10.00 billion, compared to the consensus revenue estimate of $9.87 billion.

What price target have analysts set for BIIB?

32 equities research analysts have issued 1 year target prices for Biogen's shares. Their forecasts range from $185.00 to $500.00. On average, they anticipate Biogen's share price to reach $275.47 in the next twelve months. This suggests a possible upside of 38.0% from the stock's current price.
View analysts' price targets for Biogen
or view top-rated stocks among Wall Street analysts.

Who are Biogen's key executives?
Biogen's management team includes the following people:
  • Mr. Michel Vounatsos, CEO & Director (Age 60, Pay $4.51M) (LinkedIn Profile)
  • Mr. Michael R. McDonnell CPA, Exec. VP & CFO (Age 58, Pay $1.56M)
  • Ms. Susan H. Alexander Esq., Exec. VP, Chief Legal Officer & Sec. (Age 65, Pay $1.58M)
  • Mr. Chirfi Guindo, Exec. VP and Head of Global Product Strategy & Commercialization (Age 56, Pay $1.17M)
  • Ms. Robin C. Kramer, Sr. VP & Chief Accounting Officer (Age 56)
  • Ms. Nicole Murphy, Head of Pharmaceutical Operations & Technology
  • Mr. Michael Hencke, Head of Investor Relations
  • Ms. Natacha Gassenbach, Chief Communication Officer & Head of Corp. Affairs
  • Dr. Ginger Gregory, Exec. VP & Chief HR Officer (Age 54)
  • Dr. Anabella Villalobos Ph.D., Head of Biotherapeutics & Medicinal Sciences
What is Michel Vounatsos' approval rating as Biogen's CEO?

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a number of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (10.81%), BlackRock Inc. (9.64%), Vanguard Group Inc. (8.00%), State Street Corp (4.92%), Wellington Management Group LLP (4.27%) and Clearbridge Investments LLC (1.71%). Company insiders that own Biogen stock include Alfred Sandrock, Brian S Posner and Michel Vounatsos.
View institutional ownership trends for Biogen
.

Which institutional investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Citigroup Inc., Invesco Ltd., Group One Trading L.P., PEAK6 Investments LLC, UBS Group AG, IMC Chicago LLC, and Canada Pension Plan Investment Board. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Brian S Posner.
View insider buying and selling activity for Biogen
or view top insider-selling stocks.

Which institutional investors are buying Biogen stock?

BIIB stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., BlackRock Inc., Pacer Advisors Inc., Assenagon Asset Management S.A., State Street Corp, Vanguard Group Inc., Retirement Systems of Alabama, and Federated Hermes Inc..
View insider buying and selling activity for Biogen
or or view top insider-buying stocks.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $199.65.

How much money does Biogen make?

Biogen has a market capitalization of $29.24 billion and generates $10.98 billion in revenue each year. The biotechnology company earns $1.56 billion in net income (profit) each year or $9.769990 on an earnings per share basis.

How many employees does Biogen have?

Biogen employs 9,610 workers across the globe.

Does Biogen have any subsidiaries?

The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.

When was Biogen founded?

Biogen was founded in 1978.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (617) 679-2000, via email at [email protected], or via fax at 617-679-2617.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.